Our research portfolio spans hypoxia adaptation, metabolic signaling, and microbiome-mediated oxygen biology.
Oxxyslab® — reported in the scientific literature as Oxxyslab, SLAB51, and SivoMixx — is supported by a growing body of peer-reviewed clinical and preclinical research.
The publications below are organized by major research domains to reflect both mechanistic investigations and outcome-based studies. Select any category to explore individual papers and concise summaries.
Oxygen availability is fundamental to cellular energy production and physiologic resilience under stress. Clinical and preclinical studies with Oxxyslab (reported in the literature as Oxxyslab, SLAB51, and SivoMixx) demonstrate reduced desaturation and improved maintenance of blood oxygen levels under hypoxic conditions. These findings support a gut-mediated, oxygen-sparing mechanism that enhances oxygen efficiency when demand increases.
A clinical study evaluating SLAB51/Oxxyslab under high-altitude conditions. The work focuses on oxygen saturation and acclimatization outcomes during hypoxic exposure.
A clinical evaluation of bacteriotherapy during exertion at altitude. The study centers on lactate response as a marker of metabolic efficiency under hypoxic stress.
A clinical study in oxygen-treated preterm infants evaluating oxygenation outcomes with SLAB51. The paper supports feasibility and oxygenation-related endpoints in a vulnerable population.
A preclinical mechanistic study assessing SLAB51-derived lysate under hypoxic conditions and inflammatory challenge. Provides mechanistic support linking SLAB51 to hypoxia-response biology and inflammatory modulation.
A clinical paper examining bacteriotherapy in COVID-19 patients with hypoxemia. Focuses on oxygenation-related clinical outcomes in a respiratory-compromised setting.
A clinical study exploring post-COVID symptom outcomes in patients receiving bacteriotherapy. The focus is chronic fatigue occurrence following COVID-19.
A clinical study evaluating oxygen-related endpoints in COVID-19 patients receiving bacteriotherapy. Positioned around oxygen efficiency/“oxygen-sparing” effects under respiratory stress.
A retrospective clinical cohort study evaluating outcomes in COVID-19 patients receiving oral bacteriotherapy. Supports real-world clinical evidence in a hospitalized/managed-care context.
A clinically oriented paper framing COVID-19 management challenges and adjunctive strategies. Serves as context and rationale for supportive approaches during COVID-19 rather than a single endpoint study.
A preclinical Alzheimer’s disease model paper examining microbiota modulation with SLAB51. Focuses on neuro-related pathways and systemic signals tied to gut–brain interactions.
A preclinical Alzheimer’s model paper exploring antioxidant/neuroprotective outcomes and signaling pathways with SLAB51. Provides mechanistic plausibility for neuroprotection linked to microbiota intervention.
A preclinical Parkinson’s-focused study assessing SLAB51 in both in vitro and in vivo settings. Centers on gut–brain axis relevance and Parkinson’s-related endpoints.
A preclinical Alzheimer’s model study linking microbiota intervention with metabolic control (glucose homeostasis) and neurodegeneration context. Useful for bridging neurodegenerative and metabolic narratives.
A preclinical paper framing microbiota modification strategies in Alzheimer’s disease with hypoxia-response biology context (HIF-1–related framing). Supports the mechanistic bridge between gut microbiota and brain outcomes.
A preclinical study examining inflammation/oxidative stress under sleep restriction with probiotic supplementation. Relevant to resilience, recovery, and neuroinflammation-adjacent outcomes.
A preclinical Parkinson’s rat model paper focused on longer-term probiotic intervention and recovery-related outcomes. Supports gut–brain axis modulation and functional recovery framing.
A preclinical study evaluating oral probiotic treatment in a chemotherapy-induced neuropathic pain model. Relevant to gut–systemic signaling and symptom modulation.
A preclinical zebrafish study examining SLAB51’s impact on BPA-related toxicity and the gut microbiota–liver–brain axis. Supports multi-organ axis framing and microbiota resilience.
A clinical veterinary study assessing probiotic effects on fecal microbiota and clinical/immune parameters. Useful for safety/tolerability and microbiota modulation in real-world veterinary settings.
A clinical veterinary hospital study evaluating SLAB51 use in chronic GI disease cases. Provides applied/real-world experience in an institutional veterinary setting.
Physical exertion increases oxygen demand and metabolic stress, particularly during sustained or high-intensity activity. Studies in this category investigate whether Oxxyslab supports more efficient oxygen utilization, improved metabolic balance, and resilience during exercise by modulating energy pathways and reducing physiological strain.
Reduced oxygen availability—whether due to illness, environmental exposure, or developmental immaturity—can impair cellular energy production and organ function. Studies in this category evaluate whether Oxxyslab® (SLAB51) supports improved oxygen utilization and systemic oxygenation across diverse hypoxic conditions in both clinical and environmental settings.
Reduced oxygen availability—whether due to illness, environmental exposure, or developmental immaturity—can impair cellular energy production and organ function. Studies in this category evaluate whether Oxxyslab® (SLAB51) supports improved oxygen utilization and systemic oxygenation across diverse hypoxic conditions in both clinical and environmental settings.
At the mechanistic level, Oxxyslab has been shown to influence pathways involved in oxygen sensing, mitochondrial integrity, and cellular energy production. These studies provide biological context for observed clinical and physiological outcomes.
